Camstent is a privately funded company based in Cambridge, UK, that specializes in developing innovative solutions to combat hospital acquired infections (HAIs). Through their groundbreaking anti-microbial polymer coating technology, Camstent has been able to significantly reduce biofilms on silicon-based medical devices, such as Foley catheters, which are commonly associated with urinary tract infections. HAIs are a major global concern, costing healthcare systems billions of dollars each year and negatively impacting patient health and hospital budgets.

By reducing biofilms, Camstent's technology aims to minimize infection-related issues, resulting in improved patient comfort, shorter hospital stays, reduced use of antibiotics, and lower costs. Camstent is currently conducting clinical studies on their coated Foley Catheter, with promising results showing a remarkable 61%-98% reduction in biofilms. The company is actively seeking commercial partners for their Foley catheters, collaboration projects for coating new catheters, and licensing partners for their unique coating technology.

With their commitment to innovation and improving patient outcomes, Camstent is poised to make a significant impact in the fight against HAIs